| Scrip Code | 500257 |
|---|---|
| NSE Symbol | LUPIN |
| MSEI Symbol | NOTLISTED |
| ISIN | INE326A01037 |
| Name of company | Lupin Limited |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2025 |
| Date of end of financial year | 31-03-2026 |
| Date of board meeting when results were approved | 06-11-2025 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 22-10-2025 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | Second quarter |
| Nature of report standalone or consolidated | Consolidated |
| Whether results are audited or unaudited for the quarter ended | Unaudited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | Unaudited |
| Segment Reporting | Multi segment |
| Description of single segment | |
| Start date and time of board meeting | 06-11-2025 13:00:00 |
| End date and time of board meeting | 06-11-2025 18:05:00 |
| Whether cash flow statement is applicable on company | Yes |
| Type of cash flow statement | Cash Flow Indirect |
| Declaration of unmodified opinion or statement on impact of audit qualification | Not applicable |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-07-2025 | 01-04-2025 |
| B | Date of end of reporting period | 30-09-2025 | 30-09-2025 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| 1 | Income | ||
| Revenue from operations | 7,04,751.00 | 13,31,585.00 | |
| Other income | 9,000.00 | 16,904.00 | |
| Total income | 7,13,751.00 | 13,48,489.00 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 1,13,915.00 | 2,26,578.00 |
| (b) | Purchases of stock-in-trade | 72,492.00 | 1,43,887.00 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | (3,930.00) | (10,795.00) |
| (d) | Employee benefit expense | 1,10,556.00 | 2,18,856.00 |
| (e) | Finance costs | 10,759.00 | 19,935.00 |
| (f) | Depreciation, depletion and amortisation expense | 31,677.00 | 61,575.00 |
| (f) | Other Expenses | ||
| 1 | Other expenses | 1,97,958.00 | 3,75,162.00 |
| 2 | Net (gain) / loss on foreign currency transactions | (20,373.00) | (28,960.00) |
| Total other expenses | 1,77,585.00 | 3,46,202.00 | |
| Total expenses | 5,13,054.00 | 10,06,238.00 | |
| 3 | Total profit before exceptional items and tax | 2,00,697.00 | 3,42,251.00 |
| 4 | Exceptional items | 0.00 | 0.00 |
| 5 | Total profit before tax | 2,00,697.00 | 3,42,251.00 |
| 6 | Tax expense | ||
| 7 | Current tax | 32,399.00 | 81,488.00 |
| 8 | Deferred tax | 19,815.00 | (9,866.00) |
| 9 | Total tax expenses | 52,214.00 | 71,622.00 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | 1,48,483.00 | 2,70,629.00 |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 14 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 |
| 16 | Total profit (loss) for period | 1,48,483.00 | 2,70,629.00 |
| 17 | Other comprehensive income net of taxes | 9,582.00 | 25,604.00 |
| 18 | Total Comprehensive Income for the period | 1,58,065.00 | 2,96,233.00 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | 1,47,792.00 | 2,69,695.00 | |
| Total profit or loss, attributable to non-controlling interests | 691.00 | 934.00 | |
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | 1,57,349.00 | 2,95,079.00 | |
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | 716.00 | 1,154.00 | |
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 9,136.00 | 9,136.00 | |
| Face value of equity share capital | 2 | 2 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 32.36 | 59.05 | |
| Diluted earnings (loss) per share from continuing operations | 32.28 | 58.9 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 32.36 | 59.05 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 32.28 | 58.9 | |
| 24 | Debt equity ratio | ||
| 25 | Debt service coverage ratio | ||
| 26 | Interest service coverage ratio | ||
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | 1. The above Consolidated Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on November 06 2025. The Statutory Auditors of the Company have carried out limited review of the above Consolidated Financial Results pursuant to Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations 2015. 2. The Consolidated Financial Results include the financial results of the subsidiaries Lupin Pharmaceuticals Inc. U.S.A. Lupin Australia Pty Limited Australia Nanomi B.V. Netherlands Pharma Dynamics Proprietary Limited South Africa Hormosan Pharma GmbH Germany Multicare Pharmaceuticals Philippines Inc. Philippines Lupin Atlantis Holdings SA Switzerland Lupin Healthcare UK Limited U.K. Lupin Pharma Canada Limited Canada Generic Health Pty Limited Australia Lupin Mexico S.A. de C.V. Mexico Lupin Philippines Inc. Philippines Lupin Diagnostics Limited India Generic Health SDN. BHD. Malaysia Lupin Inc. U.S.A. Laboratorios Grin S.A. de C.V. Mexico Medquimica Industria Farmaceutica LTDA Brazil Novel Laboratories Inc. U.S.A. Lupin Research Inc. U.S.A. Lupin Management Inc. U.S.A Lupin Europe GmbH Germany Lupin Biologics Limited India Lupin Oncology Inc. U.S.A Lupin Digital Health Limited India Avenue Coral Springs LLC U.S.A. Southern Cross Pharma Pty Ltd Australia Lupin Life Sciences Limited India formerly known as Lupin Atharv Ability Limited India Lupin Manufacturing Solutions Limited India Medisol S.A.S. France Lupin Lanka Private Ltd. Sri Lanka w.e.f. August 05 2024 Lupin NZ Ltd. New Zealand w.e.f. August 08 2024 Lupinlife Consumer Healthcare Limited India w.e.f. March 08 2025 Renascience Pharma Limited U.K. w.e.f. April 02 2025 and a joint venture YL Biologics Limited Japan. 3. The Consolidated Financial Statements are prepared in accordance with Ind AS 110 Consolidated Financial Statements and Ind AS 28 Investments in Associates and Joint Ventures. 4. During the quarter ended September 30 2025 41745 year to date 192823 equity shares of Rs. 2 each fully paid up were allotted upon exercise of the vested stock options pursuant to the Lupin Employees Stock Option Plans ESOPs resulting in an increase in the paid up share capital by Rs. 0.1 million year to date Rs. 0.4 million and securities premium account by Rs. 69.5 million year to date Rs. 215.6 million. 5. During the quarter ended September 30 2025 the Company through its wholly owned subsidiary Nanomi B.V. Netherlands Nanomi has entered into a definitive agreement to acquire 100% share capital of VISUfarma B.V. Netherlands for a consideration of Euro 190.0 million subject to closing adjustments. Pending regulatory approval no impact has been given in the results. The acquisition related costs are accounted in Other expenses. 6. During the quarter ended June 30 2025 the Company through its wholly owned step down subsidiary Lupin Healthcare UK Limited U.K. acquired 100% equity share capital of Renascience Pharma Limited U.K. for a consideration of Rs. 1361.6 million GBP 12.3 million. Fair value of intangibles acquired Rs. 1239.4 million deferred tax liability Rs. 309.8 million Goodwill Rs. 325.9 million has been accounted based on report of independent valuer. 7. As approved by the Members of the Company at the 43rd Annual General Meeting held on August 11 2025 the Company has disbursed on August 14 2025 a final dividend of Rs. 12 per equity share of the face value of Rs. 2 each aggregating Rs. 5481.0 million. 8. During the quarter six months ended September 30 2024 and year ended March 31 2025 the Group has made a provision of Rs. 585.1 million and Rs. 1441.2 million respectively towards ongoing disputes. 9. During the six months ended September 30 2024 and year ended March 31 2025 Lupin Limited and its subsidiary agreed to settle the dispute for an amount of USD 9.0 million Rs.750.5 million in connection with the drug Glumetza® without admitting any liability for any wrongdoing with a view to avoid the costs and uncertainties of continued litigation. 10. During the year ended March 31 2025 the Group has recognised an impairment charge of Rs 1209.0 million related to certain property plant and equipment capital work in progress intangible assets intangible assets under development and goodwill. |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | Year ended (dd-mm-yyyy) | ||
|---|---|---|---|
| Date of start of reporting period | 01-04-2025 | ||
| Date of end of reporting period | 30-09-2025 | ||
| Whether results are audited or unaudited | Unaudited | ||
| Nature of report standalone or consolidated | Consolidated | ||
| Assets | |||
| 1 | Non-current assets | ||
| Property, plant and equipment | 5,25,557.00 | ||
| Capital work-in-progress | 59,286.00 | ||
| Investment property | 0.00 | ||
| Goodwill | 2,47,492.00 | ||
| Other intangible assets | 2,36,293.00 | ||
| Intangible assets under development | 15,892.00 | ||
| Biological assets other than bearer plants | 0.00 | ||
| Investments accounted for using equity method | 2,928.00 | ||
| Non-current financial assets | |||
| Non-current investments | 5,958.00 | ||
| Trade receivables, non-current | 0.00 | ||
| Loans, non-current | 285.00 | ||
| Other non-current financial assets | 1,32,434.00 | ||
| Total non-current financial assets | 1,38,677.00 | ||
| Deferred tax assets (net) | 67,263.00 | ||
| Other non-current assets | 30,064.00 | ||
| Total non-current assets | 13,23,452.00 | ||
| 2 | Current assets | ||
| Inventories | 5,95,496.00 | ||
| Current financial asset | |||
| Current investments | 3,24,187.00 | ||
| Trade receivables, current | 6,29,015.00 | ||
| Cash and cash equivalents | 1,32,758.00 | ||
| Bank balance other than cash and cash equivalents | 1,71,264.00 | ||
| Loans, current | 483.00 | ||
| Other current financial assets | 56,682.00 | ||
| Total current financial assets | 13,14,389.00 | ||
| Current tax assets (net) | 2,868.00 | ||
| Other current assets | 1,13,839.00 | ||
| Total current assets | 20,26,592.00 | ||
| 3 | Non-current assets classified as held for sale | 0.00 | |
| 4 | Regulatory deferral account debit balances and related deferred tax Assets | 0.00 | |
| Total assets | 33,50,044.00 | ||
| Equity and liabilities | |||
| 1 | Equity | ||
| Equity attributable to owners of parent | |||
| Equity share capital | 9,136.00 | ||
| Other equity | 19,54,123.00 | ||
| Total equity attributable to owners of parent | 19,63,259.00 | ||
| Non controlling interest | 9,578.00 | ||
| Total equity | 19,72,837.00 | ||
| 2 | Liabilities | ||
| Non-current liabilities | |||
| Non-current financial liabilities | |||
| Borrowings, non-current | 1,53,901.00 | ||
| Trade payables, non-current | |||
| (A) Total outstanding dues of micro enterprises and small enterprises | 0.00 | ||
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | 0.00 | ||
| Total Trade payable | 0.00 | ||
| Other non-current financial liabilities | 38,276.00 | ||
| Total non-current financial liabilities | 1,92,177.00 | ||
| Provisions, non-current | 48,567.00 | ||
| Deferred tax liabilities (net) | 25,593.00 | ||
| Deferred government grants, Non-current | 0.00 | ||
| Other non-current liabilities | 28,810.00 | ||
| Total non-current liabilities | 2,95,147.00 | ||
| Current liabilities | |||
| Current financial liabilities | |||
| Borrowings, current | 4,23,945.00 | ||
| Trade payables, current | |||
| (A) Total outstanding dues of micro enterprises and small enterprises | 11,915.00 | ||
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | 3,28,800.00 | ||
| Total Trade payable | 3,40,715.00 | ||
| Other current financial liabilities | 89,211.00 | ||
| Total current financial liabilities | 8,53,871.00 | ||
| Other current liabilities | 1,34,881.00 | ||
| Provisions, current | 27,857.00 | ||
| Current tax liabilities (Net) | 65,451.00 | ||
| Deferred government grants, Current | 0.00 | ||
| Total current liabilities | 10,82,060.00 | ||
| 3 | Liabilities directly associated with assets in disposal group classified as held for sale | 0.00 | |
| 4 | Regulatory deferral account credit balances and related deferred tax liability | 0.00 | |
| Total liabilities | 13,77,207.00 | ||
| Total equity and liabilites | 33,50,044.00 | ||
| Disclosure of notes on assets and liabilities | Textual Information(1) | ||
| Textual Information(1) | 1 Property Plant and Equipment includes Right of use Assets of Rs 5057.0 mn. 2 Other Non current Assets includes Non current tax assets of Rs. 475.6 mn. 3 Other Non current financial liabilities includes Lease liabilities of Rs. 3058.6 mn. 4 Other Current Financial Liabilities includes lease liabilities of Rs. 1326.8 mn. |
|---|
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-07-2025 | 01-04-2025 | |||||
| Date of end of reporting period | 30-09-2025 | 30-09-2025 | |||||
| Whether results are audited or unaudited | Unaudited | Unaudited | |||||
| Nature of report standalone or consolidated | Consolidated | Consolidated | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| 1 | Pharmaceuticals | 7,01,032.00 | 13,24,673.00 | ||||
| 2 | Others | 3,768.00 | 6,996.00 | ||||
| 3 | Less: Inter segment | 0.00 | 0.00 | ||||
| Total Segment Revenue | 7,04,800.00 | 13,31,669.00 | |||||
| Less: Inter segment revenue | 49.00 | 84.00 | |||||
| Revenue from operations | 7,04,751.00 | 13,31,585.00 | |||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| 1 | Pharmaceuticals | 2,04,799.00 | 3,50,583.00 | ||||
| 2 | Others | (4,102.00) | (8,332.00) | ||||
| 3 | Less: Inter segment | 0.00 | 0.00 | ||||
| Total Profit before tax | 2,00,697.00 | 3,42,251.00 | |||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | 2,00,697.00 | 3,42,251.00 | |||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| 1 | Pharmaceuticals | 33,24,715.00 | 33,24,715.00 | ||||
| 2 | Others | 25,552.00 | 25,552.00 | ||||
| 3 | Less: Inter segment | (223.00) | (223.00) | ||||
| Total Segment Asset | 33,50,044.00 | 33,50,044.00 | |||||
| Un-allocable Assets | 0.00 | 0.00 | |||||
| Net Segment Asset | 33,50,044.00 | 33,50,044.00 | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| 1 | Pharmaceuticals | 13,67,465.00 | 13,67,465.00 | ||||
| 2 | Others | 9,952.00 | 9,952.00 | ||||
| 3 | Less: Inter segment | (210.00) | (210.00) | ||||
| Total Segment Liabilities | 13,77,207.00 | 13,77,207.00 | |||||
| Un-allocable Liabilities | 0.00 | 0.00 | |||||
| Net Segment Liabilities | 13,77,207.00 | 13,77,207.00 | |||||
| Disclosure of notes on segments | |||||||
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-07-2025 | 01-04-2025 |
| B | Date of end of reporting period | 30-09-2025 | 30-09-2025 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Items that will not be reclassified subsequently to profit or loss | 937.00 | (98.00) |
| Total Amount of items that will not be reclassified to profit and loss | 937.00 | (98.00) | |
| 2 | Income tax relating to items that will not be reclassified to profit or loss | 428.00 | 66.00 |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| 1 | Items that will be reclassified subsequently to profit or loss | 7,543.00 | 24,492.00 |
| Total Amount of items that will be reclassified to profit and loss | 7,543.00 | 24,492.00 | |
| 4 | Income tax relating to items that will be reclassified to profit or loss | (1,530.00) | (1,276.00) |
| 5 | Total Other comprehensive income | 9,582.00 | 25,604.00 |
| Particulars | Year ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|
| A | Date of start of reporting period | 01-04-2025 | ||||
| B | Date of end of reporting period | 30-09-2025 | ||||
| C | Whether results are audited or unaudited | Unaudited | ||||
| D | Nature of report standalone or consolidated | Consolidated | ||||
| Statement of cash flows | ||||||
| Cash flows from used in operating activities | ||||||
| Profit before tax | 3,42,251.00 | |||||
| Adjustments for reconcile profit (loss) | ||||||
| Adjustments for finance costs | 19,935.00 | |||||
| Adjustments for decrease (increase) in inventories | (45,808.00) | |||||
| Adjustments for decrease (increase) in trade receivables, current | (64,284.00) | |||||
| Adjustments for decrease (increase) in trade receivables, non-current | 0.00 | |||||
| Adjustments for decrease (increase) in other current assets | 11,660.00 | |||||
| Adjustments for decrease (increase) in other non-current assets | (6,683.00) | |||||
| Adjustments for other financial assets, non-current | 1,624.00 | |||||
| Adjustments for other financial assets, current | (23,348.00) | |||||
| Adjustments for other bank balances | (11,396.00) | |||||
| Adjustments for increase (decrease) in trade payables, current | 40,044.00 | |||||
| Adjustments for increase (decrease) in trade payables, non-current | 0.00 | |||||
| Adjustments for increase (decrease) in other current liabilities | 20,589.00 | |||||
| Adjustments for increase (decrease) in other non-current liabilities | 8,299.00 | |||||
| Adjustments for depreciation and amortisation expense | 61,575.00 | |||||
| Adjustments for impairment loss reversal of impairment loss recognised in profit or loss | 0.00 | |||||
| Adjustments for provisions, current | 481.00 | |||||
| Adjustments for provisions, non-current | 2,857.00 | |||||
| Adjustments for other financial liabilities, current | 3,008.00 | |||||
| Adjustments for other financial liabilities, non-current | 2,143.00 | |||||
| Adjustments for unrealised foreign exchange losses gains | (18,350.00) | |||||
| Adjustments for dividend income | 0.00 | |||||
| Adjustments for interest income | 10,832.00 | |||||
| Adjustments for share-based payments | 2,347.00 | |||||
| Adjustments for fair value losses (gains) | (3,451.00) | |||||
| Adjustments for undistributed profits of associates | 0.00 | |||||
| Other adjustments for which cash effects are investing or financing cash flow | (2,527.00) | |||||
| Other adjustments to reconcile profit (loss) | 0.00 | |||||
| Other adjustments for non-cash items | 8,185.00 | |||||
| Share of profit and loss from partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Total adjustments for reconcile profit (loss) | (3,932.00) | |||||
| Net cash flows from (used in) operations | 3,38,319.00 | |||||
| Dividends received | 0.00 | |||||
| Interest paid | 0.00 | |||||
| Interest received | 0.00 | |||||
| Income taxes paid (refund) | 59,436.00 | |||||
| Other inflows (outflows) of cash | 0.00 | |||||
| Net cash flows from (used in) operating activities | 2,78,883.00 | |||||
| Cash flows from used in investing activities | ||||||
| Cash flows from losing control of subsidiaries or other businesses | 0.00 | |||||
| Cash flows used in obtaining control of subsidiaries or other businesses | 13,575.00 | |||||
| Other cash receipts from sales of equity or debt instruments of other entities | 0.00 | |||||
| Other cash payments to acquire equity or debt instruments of other entities | 0.00 | |||||
| Other cash receipts from sales of interests in joint ventures | 0.00 | |||||
| Other cash payments to acquire interests in joint ventures | 0.00 | |||||
| Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Cash payment for investment in partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Proceeds from sales of property, plant and equipment | 957.00 | |||||
| Purchase of property, plant and equipment | 57,380.00 | |||||
| Proceeds from sales of investment property | 0.00 | |||||
| Purchase of investment property | 0.00 | |||||
| Proceeds from sales of intangible assets | 0.00 | |||||
| Purchase of intangible assets | 0.00 | |||||
| Proceeds from sales of intangible assets under development | 0.00 | |||||
| Purchase of intangible assets under development | 0.00 | |||||
| Proceeds from sales of goodwill | 0.00 | |||||
| Purchase of goodwill | 0.00 | |||||
| Proceeds from biological assets other than bearer plants | 0.00 | |||||
| Purchase of biological assets other than bearer plants | 0.00 | |||||
| Proceeds from government grants | 0.00 | |||||
| Proceeds from sales of other long-term assets | 0.00 | |||||
| Purchase of other long-term assets | 0.00 | |||||
| Cash advances and loans made to other parties | 0.00 | |||||
| Cash receipts from repayment of advances and loans made to other parties | 0.00 | |||||
| Cash payments for future contracts, forward contracts, option contracts and swap contracts | 0.00 | |||||
| Cash receipts from future contracts, forward contracts, option contracts and swap contracts | 0.00 | |||||
| Dividends received | 0.00 | |||||
| Interest received | 10,672.00 | |||||
| Income taxes paid (refund) | 0.00 | |||||
| Other inflows (outflows) of cash | (2,13,503.00) | |||||
| Net cash flows from (used in) investing activities | (2,72,829.00) | |||||
| Cash flows from used in financing activities | ||||||
| Proceeds from changes in ownership interests in subsidiaries | 0.00 | |||||
| Payments from changes in ownership interests in subsidiaries | 0.00 | |||||
| Proceeds from issuing shares | 0.00 | |||||
| Proceeds from issuing other equity instruments | 0.00 | |||||
| Payments to acquire or redeem entity's shares | 0.00 | |||||
| Payments of other equity instruments | 0.00 | |||||
| Proceeds from exercise of stock options | 534.00 | |||||
| Proceeds from issuing debentures notes bonds etc | 0.00 | |||||
| Proceeds from borrowings | 48,741.00 | |||||
| Repayments of borrowings | 0.00 | |||||
| Payments of lease liabilities | 3,819.00 | |||||
| Dividends paid | 54,765.00 | |||||
| Interest paid | 18,356.00 | |||||
| Income taxes paid (refund) | 0.00 | |||||
| Other inflows (outflows) of cash | 0.00 | |||||
| Net cash flows from (used in) financing activities | (27,665.00) | |||||
| Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes | (21,611.00) | |||||
| Effect of exchange rate changes on cash and cash equivalents | ||||||
| Effect of exchange rate changes on cash and cash equivalents | 0.00 | |||||
| Net increase (decrease) in cash and cash equivalents | (21,611.00) | |||||
| Cash and cash equivalents cash flow statement at beginning of period | 1,54,369.00 | |||||
| Cash and cash equivalents cash flow statement at end of period | 1,32,758.00 | |||||